Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and increased by 2.5 mg every 4 weeks up to a maintenance dose of 5-15 mg based on tolerability and therapeutic response
Editorial Advisory Board Member, Harvard Health Publishing Disclaimer: As a service to our readers, Harvard Health Publishing provides access to our library of archived content
Reported applications include NNMT enzyme inhibition assays measuring 1-methylnicotinamide formation or S-adenosylhomocysteine release, intracellular target-engagement assays in differentiated 3T3-L1 adipocytes where 5-Amino-1MQ reduced intracellular 1-methylnicotinamide with an EC near 2.3 M (Neelakantan et al., Biochem Pharmacol, 2018), membrane permeability and Caco-2 transport characterisation, methyltransferase selectivity panels covering COMT, DNMT1 and PRMT3, and rodent studies of NNMT inhibition in adipose tissue and liver following the antisense knockdown work of Kraus and colleagues (Nature, 2014)
We isolate and eliminate those variables
